Remember the 2019 publication cited repeatedly in support of TT's 'agnostic' anti-cancer properties, one finding was 'Efficacy signals found in squamous cell carcinoma (SCC), melanoma (BRAF), basal cell carcinoma (BCC) etc etc'. Under heading 'Strong efficacy signals from a first-in-human, dose-escalation safety trial' in the Human Ocology page on the website.
Its 2024, things moving along at a galcial place despite hundreds of millions raised. Plus several more mouths to feed. We saw what happened with the melanoma trials and the commercial dud that is stelfonta to date. Not expecting much at all, we shall see if something concrete materializes.
